Generated by AI
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing long-acting antibodies and antibody combinations for inflammatory bowel disease and other immune-mediated disorders. Spyre Therapeutics concentrates on advancing therapies designed to improve disease control, extend treatment durability, and simplify dosing for patients with ulcerative colitis, Crohn’s disease, and related rheumatic conditions. Its current pipeline centers on investigational antibody programs targeting key immune pathways, including α4β7, TL1A, and IL-23, with both standalone and combination approaches under development. The company is primarily engaged in biopharmaceutical research and clinical development, and its work is centered on creating next-generation immunology treatments for complex chronic diseases. Headquartered in Waltham, Massachusetts, Spyre Therapeutics serves as a specialized player in the biotech sector, where it contributes to the advancement of targeted therapies for gastrointestinal and immune-mediated diseases.
WebsiteBuilding 23
Waltham, MA, 02453
United States
The latest articles about SYRE.
Investing.com-- Jefferies said Spyre Therapeutics remained its top pick in the small- to mid-cap biotech sector heading into 2027, lauding its pipeline of combination therapies for inflammatory bowel disease.
Summary of Aug 26's posts. Generated by AI.
Summary of Apr 13's posts. Generated by AI.
Detailed price information for Spyre Therapeutics Inc (SYRE-Q) from The Globe and Mail including charting and trades.
No summary yet.
No summary yet.
Investors talking about SYRE also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.